Heron Therapeutics Inc
HRTX1.735USD
+0.045+2.66%
交易中 （美東）報價延遲15分鐘
264.46M總市值
虧損本益比TTM
關於 Heron Therapeutics Inc 公司
Heron Therapeutics, Inc. 是一家商業階段的生物技術公司。該公司將一系列產品商業化，用於護理急性護理和腫瘤患者。其腫瘤護理產品組合包括 SUSTOL 和 CINVANTI。SUSTOL 用於預防與中度致吐化療 (MEC) 以及蒽環類和環磷酰胺 (AC) 聯合化療方案相關的急性和延遲性惡心和嘔吐。CINVANTI 是阿瑞吡坦的靜脈 (IV) 製劑，阿瑞吡坦是一種 P 物質/神經激肽-1 (NK1) 受體拮抗劑。其急性護理產品組合包括 ZYNRELEF 和 APONVIE。HTX- ZYNRELEF 是一種雙作用局部麻醉劑，可提供局部麻醉劑布比卡因和低劑量非甾體抗炎藥美洛昔康的固定劑量組合。 APONVIE 是一種 NK1 受體拮抗劑的靜脈注射劑型，用於治療術後噁心嘔吐 (PONV)。其產品在美國銷售。
公司簡介
公司代碼HRTX
公司名稱Heron Therapeutics Inc
上市日期Aug 26, 1987
CEOMr. Craig Alexander Collard
員工數量122
證券類型Ordinary Share
年結日Aug 26
公司地址100 Regency Forest Drive
城市CARY
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編27518
電話18582514400
網址https://www.herontx.com/
公司代碼HRTX
上市日期Aug 26, 1987
CEOMr. Craig Alexander Collard
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
420.81K
+3.39%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
152.52K
+2.61%
Dr. William P. (Bill) Forbes
Dr. William P. (Bill) Forbes
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
138.94K
+2.87%
Dr. Sharmila Dissanaike, M.D.
Dr. Sharmila Dissanaike, M.D.
Independent Director
Independent Director
68.45K
-3.44%
Mr. Christian Waage
Mr. Christian Waage
Independent Director
Independent Director
66.18K
+26.70%
Mr. Craig A. Johnson
Mr. Craig A. Johnson
Lead Independent Director
Lead Independent Director
65.82K
-5.73%
Mr. Adam Morgan
Mr. Adam Morgan
Chairman of the Board
Chairman of the Board
32.89K
+19.94%
Mr. Michael Kaseta
Mr. Michael Kaseta
Independent Director
Independent Director
2.37K
-95.76%
Mr. Mark Hensley
Mr. Mark Hensley
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
420.81K
+3.39%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
152.52K
+2.61%
Dr. William P. (Bill) Forbes
Dr. William P. (Bill) Forbes
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
138.94K
+2.87%
Dr. Sharmila Dissanaike, M.D.
Dr. Sharmila Dissanaike, M.D.
Independent Director
Independent Director
68.45K
-3.44%
Mr. Christian Waage
Mr. Christian Waage
Independent Director
Independent Director
66.18K
+26.70%
Mr. Craig A. Johnson
Mr. Craig A. Johnson
Lead Independent Director
Lead Independent Director
65.82K
-5.73%
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
業務USD
名稱
營收
佔比
CINVANTI
25.74M
66.17%
ZYNRELEF
8.04M
20.67%
SUSTOL
2.86M
7.35%
APONVIE
2.26M
5.81%
地區USD
名稱
營收
佔比
United States
38.90M
100.00%
業務
地區
業務USD
名稱
營收
佔比
CINVANTI
25.74M
66.17%
ZYNRELEF
8.04M
20.67%
SUSTOL
2.86M
7.35%
APONVIE
2.26M
5.81%
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Rubric Capital Management LP
17.51%
The Vanguard Group, Inc.
5.39%
Adage Capital Management, L.P.
5.15%
BlackRock Institutional Trust Company, N.A.
5.11%
Velan Capital Investment Management LP
4.58%
Other
62.26%
持股股東
持股股東
佔比
Rubric Capital Management LP
17.51%
The Vanguard Group, Inc.
5.39%
Adage Capital Management, L.P.
5.15%
BlackRock Institutional Trust Company, N.A.
5.11%
Velan Capital Investment Management LP
4.58%
Other
62.26%
股東類型
持股股東
佔比
Hedge Fund
35.76%
Investment Advisor
24.53%
Investment Advisor/Hedge Fund
16.56%
Research Firm
3.08%
Private Equity
1.45%
Pension Fund
1.17%
Individual Investor
0.70%
Bank and Trust
0.14%
Venture Capital
0.06%
Other
16.54%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
350
127.68M
83.69%
-21.02M
2025Q1
384
126.94M
83.22%
-22.20M
2024Q4
390
118.52M
78.10%
-45.51M
2024Q3
400
125.21M
82.85%
-42.71M
2024Q2
402
132.96M
88.55%
-36.75M
2024Q1
402
122.65M
81.87%
-45.18M
2023Q4
413
115.58M
77.36%
-37.11M
2023Q3
417
122.12M
87.17%
-25.94M
2023Q2
428
102.54M
85.75%
-39.37M
2023Q1
447
111.46M
93.56%
-41.46M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Rubric Capital Management LP
26.71M
17.51%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
8.23M
5.39%
+67.98K
+0.83%
Mar 31, 2025
Adage Capital Management, L.P.
7.85M
5.15%
-648.00K
-7.62%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.79M
5.11%
-114.84K
-1.45%
Mar 31, 2025
Velan Capital Investment Management LP
6.99M
4.58%
--
--
Apr 21, 2025
Palisade Capital Management, LLC
5.29M
3.47%
+1.36M
+34.65%
Mar 31, 2025
Point72 Asset Management, L.P.
4.78M
3.13%
+1.70M
+55.27%
Mar 31, 2025
Tejara Capital Ltd.
4.58M
3%
-84.14K
-1.80%
Mar 31, 2025
State Street Global Advisors (US)
3.25M
2.13%
+107.71K
+3.42%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.11M
2.04%
+98.40K
+3.26%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.5%
iShares Micro-Cap ETF
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
Principal U.S. Small-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0.5%
iShares Micro-Cap ETF
佔比0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.02%
Principal U.S. Small-Cap ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.02%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
Schwab U.S. Small-Cap ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
